Current treatment options for craniofacial hyperhidrosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Vascular Brasileiro (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413 |
Resumo: | Abstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely. |
id |
SBACV-1_eb1788fb47b32899da97f16b3db88232 |
---|---|
oai_identifier_str |
oai:scielo:S1677-54492020000100413 |
network_acronym_str |
SBACV-1 |
network_name_str |
Jornal Vascular Brasileiro (Online) |
repository_id_str |
|
spelling |
Current treatment options for craniofacial hyperhidrosishyperhidrosissympathectomyoxybutyninAbstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely.Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)2020-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413Jornal Vascular Brasileiro v.19 2020reponame:Jornal Vascular Brasileiro (Online)instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)instacron:SBACV10.1590/1677-5449.200152info:eu-repo/semantics/openAccessWolosker,NelsonFaustino,Carolina BritoSilva,Marcelo Fiorelli Alexandrino daCampos,José Ribas Milanez deKauffman,Pauloeng2020-11-13T00:00:00Zoai:scielo:S1677-54492020000100413Revistahttp://www.scielo.br/jvbhttps://old.scielo.br/oai/scielo-oai.php||secretaria@sbacv.org.br1677-73011677-5449opendoar:2020-11-13T00:00Jornal Vascular Brasileiro (Online) - Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)false |
dc.title.none.fl_str_mv |
Current treatment options for craniofacial hyperhidrosis |
title |
Current treatment options for craniofacial hyperhidrosis |
spellingShingle |
Current treatment options for craniofacial hyperhidrosis Wolosker,Nelson hyperhidrosis sympathectomy oxybutynin |
title_short |
Current treatment options for craniofacial hyperhidrosis |
title_full |
Current treatment options for craniofacial hyperhidrosis |
title_fullStr |
Current treatment options for craniofacial hyperhidrosis |
title_full_unstemmed |
Current treatment options for craniofacial hyperhidrosis |
title_sort |
Current treatment options for craniofacial hyperhidrosis |
author |
Wolosker,Nelson |
author_facet |
Wolosker,Nelson Faustino,Carolina Brito Silva,Marcelo Fiorelli Alexandrino da Campos,José Ribas Milanez de Kauffman,Paulo |
author_role |
author |
author2 |
Faustino,Carolina Brito Silva,Marcelo Fiorelli Alexandrino da Campos,José Ribas Milanez de Kauffman,Paulo |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Wolosker,Nelson Faustino,Carolina Brito Silva,Marcelo Fiorelli Alexandrino da Campos,José Ribas Milanez de Kauffman,Paulo |
dc.subject.por.fl_str_mv |
hyperhidrosis sympathectomy oxybutynin |
topic |
hyperhidrosis sympathectomy oxybutynin |
description |
Abstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492020000100413 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1677-5449.200152 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) |
publisher.none.fl_str_mv |
Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) |
dc.source.none.fl_str_mv |
Jornal Vascular Brasileiro v.19 2020 reponame:Jornal Vascular Brasileiro (Online) instname:Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) instacron:SBACV |
instname_str |
Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) |
instacron_str |
SBACV |
institution |
SBACV |
reponame_str |
Jornal Vascular Brasileiro (Online) |
collection |
Jornal Vascular Brasileiro (Online) |
repository.name.fl_str_mv |
Jornal Vascular Brasileiro (Online) - Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV) |
repository.mail.fl_str_mv |
||secretaria@sbacv.org.br |
_version_ |
1752126648549900288 |